Parathyroid  ||| S:0 E:12 ||| JJ
hormone  ||| S:12 E:20 ||| NN
and  ||| S:20 E:24 ||| CC
its  ||| S:24 E:28 ||| PRP$
analogues  ||| S:28 E:38 ||| NN
-  ||| S:38 E:40 ||| :
molecular  ||| S:40 E:50 ||| JJ
mechanisms  ||| S:50 E:61 ||| NNS
of  ||| S:61 E:64 ||| IN
action  ||| S:64 E:71 ||| NN
and  ||| S:71 E:75 ||| CC
efficacy  ||| S:75 E:84 ||| NN
of  ||| S:84 E:87 ||| IN
osteoporosis  ||| S:87 E:100 ||| JJ
therapy  ||| S:100 E:108 ||| NN
Most  ||| S:108 E:113 ||| RBS
medical  ||| S:113 E:121 ||| JJ
agents  ||| S:121 E:128 ||| NNS
currently  ||| S:128 E:138 ||| RB
applied  ||| S:138 E:146 ||| VBN
in  ||| S:146 E:149 ||| IN
osteoporosis  ||| S:149 E:162 ||| JJ
therapy  ||| S:162 E:170 ||| NN
act  ||| S:170 E:174 ||| NN
by  ||| S:174 E:177 ||| IN
inhibiting  ||| S:177 E:188 ||| JJ
bone  ||| S:188 E:193 ||| NN
resorption  ||| S:193 E:204 ||| NNS
and  ||| S:204 E:208 ||| CC
reducing  ||| S:208 E:217 ||| VBG
bone  ||| S:217 E:222 ||| NN
remodelling ||| S:222 E:233 ||| NN
,  ||| S:233 E:235 ||| ,
i.e.  ||| S:235 E:240 ||| VBZ
they  ||| S:240 E:245 ||| PRP
inhibit  ||| S:245 E:253 ||| VBP
the  ||| S:253 E:257 ||| DT
process  ||| S:257 E:265 ||| NN
of  ||| S:265 E:268 ||| IN
bone  ||| S:268 E:273 ||| NN
mass  ||| S:273 E:278 ||| NN
loss  ||| S:278 E:283 ||| NN
by  ||| S:283 E:286 ||| IN
suppressing  ||| S:286 E:298 ||| JJ
bone  ||| S:298 E:303 ||| NN
resorption  ||| S:303 E:314 ||| NN
processes ||| S:314 E:323 ||| NNS
.  ||| S:323 E:325 ||| .
These  ||| S:325 E:331 ||| DT
drugs  ||| S:331 E:337 ||| NNS
provide  ||| S:337 E:345 ||| VBP
an  ||| S:345 E:348 ||| DT
ideal  ||| S:348 E:354 ||| JJ
therapeutic  ||| S:354 E:366 ||| JJ
option  ||| S:366 E:373 ||| NN
to  ||| S:373 E:376 ||| TO
prevent  ||| S:376 E:384 ||| VB
osteoporosis  ||| S:384 E:397 ||| JJ
progression ||| S:397 E:408 ||| NN
.  ||| S:408 E:410 ||| .
They  ||| S:410 E:415 ||| PRP
however  ||| S:415 E:423 ||| RB
have  ||| S:423 E:428 ||| VB
a  ||| S:428 E:430 ||| DT
rather  ||| S:430 E:437 ||| RB
limited  ||| S:437 E:445 ||| JJ
usefulness  ||| S:445 E:456 ||| NN
when  ||| S:456 E:461 ||| WRB
the  ||| S:461 E:465 ||| DT
disease  ||| S:465 E:473 ||| NN
has  ||| S:473 E:477 ||| VBZ
already  ||| S:477 E:485 ||| RB
reached  ||| S:485 E:493 ||| VBN
its  ||| S:493 E:497 ||| PRP$
advanced  ||| S:497 E:506 ||| JJ
stages  ||| S:506 E:513 ||| NNS
with  ||| S:513 E:518 ||| IN
distinctive  ||| S:518 E:530 ||| JJ
bone  ||| S:530 E:535 ||| NN
architecture  ||| S:535 E:548 ||| NN
lesions ||| S:548 E:555 ||| NNS
.  ||| S:555 E:557 ||| .
The  ||| S:557 E:561 ||| DT
fracture  ||| S:561 E:570 ||| JJ
risk  ||| S:570 E:575 ||| NN
reduction  ||| S:575 E:585 ||| NN
rate ||| S:585 E:589 ||| NN
,  ||| S:589 E:591 ||| ,
achieved  ||| S:591 E:600 ||| VBN
in  ||| S:600 E:603 ||| IN
the  ||| S:603 E:607 ||| DT
course  ||| S:607 E:614 ||| NN
of  ||| S:614 E:617 ||| IN
anti-resorptive  ||| S:617 E:633 ||| JJ
therapy ||| S:633 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
is  ||| S:642 E:645 ||| VBZ
insufficient  ||| S:645 E:658 ||| JJ
for  ||| S:658 E:662 ||| IN
patients  ||| S:662 E:671 ||| NNS
with  ||| S:671 E:676 ||| IN
severe  ||| S:676 E:683 ||| JJ
osteoporosis  ||| S:683 E:696 ||| NN
to  ||| S:696 E:699 ||| TO
stop  ||| S:699 E:704 ||| VB
the  ||| S:704 E:708 ||| DT
downward  ||| S:708 E:717 ||| JJ
spiral  ||| S:717 E:724 ||| NN
of  ||| S:724 E:727 ||| IN
their  ||| S:727 E:733 ||| PRP$
quality  ||| S:733 E:741 ||| NN
of  ||| S:741 E:744 ||| IN
life  ||| S:744 E:749 ||| NN
( ||| S:749 E:750 ||| -LRB-
QoL ||| S:750 E:753 ||| NNP
)  ||| S:753 E:755 ||| -RRB-
with  ||| S:755 E:760 ||| IN
a  ||| S:760 E:762 ||| DT
simultaneously  ||| S:762 E:777 ||| RB
increasing  ||| S:777 E:788 ||| VBG
threat  ||| S:788 E:795 ||| NN
of  ||| S:795 E:798 ||| IN
premature  ||| S:798 E:808 ||| JJ
death ||| S:808 E:813 ||| NN
.  ||| S:813 E:815 ||| .
The  ||| S:815 E:819 ||| DT
activity  ||| S:819 E:828 ||| NN
of  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
N-terminal  ||| S:835 E:846 ||| JJ
fragment  ||| S:846 E:855 ||| NN
of  ||| S:855 E:858 ||| IN
1-34  ||| S:858 E:863 ||| CD
human  ||| S:863 E:869 ||| JJ
parathormone  ||| S:869 E:882 ||| NNS
( ||| S:882 E:883 ||| -LRB-
teriparatide  ||| S:883 E:896 ||| NN
-  ||| S:896 E:898 ||| :
1-34  ||| S:898 E:903 ||| NNP
rhPTH ||| S:903 E:908 ||| NNP
) ||| S:908 E:909 ||| -RRB-
,  ||| S:909 E:911 ||| ,
a  ||| S:911 E:913 ||| DT
parathyroid  ||| S:913 E:925 ||| JJ
hormone  ||| S:925 E:933 ||| NN
( ||| S:933 E:934 ||| -LRB-
PTH ||| S:934 E:937 ||| NNP
)  ||| S:937 E:939 ||| -RRB-
analogue  ||| S:939 E:948 ||| VBZ
obtained  ||| S:948 E:957 ||| VBN
via  ||| S:957 E:961 ||| IN
genetic  ||| S:961 E:969 ||| JJ
engineering  ||| S:969 E:981 ||| NN
,  ||| S:981 E:983 ||| ,
is  ||| S:983 E:986 ||| VBZ
expressed  ||| S:986 E:996 ||| VBN
by  ||| S:996 E:999 ||| IN
increased  ||| S:999 E:1009 ||| JJ
bone  ||| S:1009 E:1014 ||| NN
metabolism ||| S:1014 E:1024 ||| NN
,  ||| S:1024 E:1026 ||| ,
while  ||| S:1026 E:1032 ||| IN
promoting  ||| S:1032 E:1042 ||| VBG
new  ||| S:1042 E:1046 ||| JJ
bone  ||| S:1046 E:1051 ||| NN
tissue  ||| S:1051 E:1058 ||| NN
formation  ||| S:1058 E:1068 ||| NN
by  ||| S:1068 E:1071 ||| IN
stimulating  ||| S:1071 E:1083 ||| VBG
the  ||| S:1083 E:1087 ||| DT
activity  ||| S:1087 E:1096 ||| NN
of  ||| S:1096 E:1099 ||| IN
osteoblasts  ||| S:1099 E:1111 ||| VBG
more  ||| S:1111 E:1116 ||| JJR
than  ||| S:1116 E:1121 ||| IN
that  ||| S:1121 E:1126 ||| DT
of  ||| S:1126 E:1129 ||| IN
osteoclasts ||| S:1129 E:1140 ||| NN
.  ||| S:1140 E:1142 ||| .
The  ||| S:1142 E:1146 ||| DT
anabolic  ||| S:1146 E:1155 ||| JJ
activity  ||| S:1155 E:1164 ||| NN
of  ||| S:1164 E:1167 ||| IN
PTH  ||| S:1167 E:1171 ||| NNP
includes  ||| S:1171 E:1180 ||| VBZ
both  ||| S:1180 E:1185 ||| PDT
its  ||| S:1185 E:1189 ||| PRP$
direct  ||| S:1189 E:1196 ||| JJ
effect  ||| S:1196 E:1203 ||| NN
on  ||| S:1203 E:1206 ||| IN
the  ||| S:1206 E:1210 ||| DT
osteoblast  ||| S:1210 E:1221 ||| JJ
cell  ||| S:1221 E:1226 ||| NN
line ||| S:1226 E:1230 ||| NN
,  ||| S:1230 E:1232 ||| ,
and  ||| S:1232 E:1236 ||| CC
its  ||| S:1236 E:1240 ||| PRP$
indirect  ||| S:1240 E:1249 ||| JJ
actions  ||| S:1249 E:1257 ||| NNS
exerted  ||| S:1257 E:1265 ||| VBN
via  ||| S:1265 E:1269 ||| IN
its  ||| S:1269 E:1273 ||| PRP$
regulatory  ||| S:1273 E:1284 ||| JJ
effects  ||| S:1284 E:1292 ||| NNS
on  ||| S:1292 E:1295 ||| IN
selected  ||| S:1295 E:1304 ||| JJ
growth  ||| S:1304 E:1311 ||| NN
factors ||| S:1311 E:1318 ||| NNS
,  ||| S:1318 E:1320 ||| ,
e.g.  ||| S:1320 E:1325 ||| NNP
IGF-1  ||| S:1325 E:1331 ||| NNP
or  ||| S:1331 E:1334 ||| CC
sclerostin ||| S:1334 E:1344 ||| NN
.  ||| S:1344 E:1346 ||| .
However ||| S:1346 E:1353 ||| RB
,  ||| S:1353 E:1355 ||| ,
the  ||| S:1355 E:1359 ||| DT
molecular  ||| S:1359 E:1369 ||| JJ
mechanisms  ||| S:1369 E:1380 ||| NNS
responsible  ||| S:1380 E:1392 ||| JJ
for  ||| S:1392 E:1396 ||| IN
the  ||| S:1396 E:1400 ||| DT
actual  ||| S:1400 E:1407 ||| JJ
anabolic  ||| S:1407 E:1416 ||| JJ
effects  ||| S:1416 E:1424 ||| NNS
of  ||| S:1424 E:1427 ||| IN
PTH  ||| S:1427 E:1431 ||| NNP
remain  ||| S:1431 E:1438 ||| VBP
mostly  ||| S:1438 E:1445 ||| RB
still  ||| S:1445 E:1451 ||| RB
unclear ||| S:1451 E:1458 ||| JJ
.  ||| S:1458 E:1460 ||| .
Clinical  ||| S:1460 E:1469 ||| JJ
studies  ||| S:1469 E:1477 ||| NNS
have  ||| S:1477 E:1482 ||| VBP
demonstrated  ||| S:1482 E:1495 ||| VBN
that  ||| S:1495 E:1500 ||| IN
therapeutic  ||| S:1500 E:1512 ||| JJ
protocols  ||| S:1512 E:1522 ||| NNS
with  ||| S:1522 E:1527 ||| IN
the  ||| S:1527 E:1531 ||| DT
application  ||| S:1531 E:1543 ||| NN
of  ||| S:1543 E:1546 ||| IN
PTH  ||| S:1546 E:1550 ||| NNP
analogues  ||| S:1550 E:1560 ||| NNS
provide  ||| S:1560 E:1568 ||| VBP
an  ||| S:1568 E:1571 ||| DT
effective  ||| S:1571 E:1581 ||| JJ
protection  ||| S:1581 E:1592 ||| NN
against  ||| S:1592 E:1600 ||| IN
all  ||| S:1600 E:1604 ||| DT
osteoporotic  ||| S:1604 E:1617 ||| JJ
fracture  ||| S:1617 E:1626 ||| NN
types  ||| S:1626 E:1632 ||| NNS
in  ||| S:1632 E:1635 ||| IN
post-menopausal  ||| S:1635 E:1651 ||| JJ
women  ||| S:1651 E:1657 ||| NNS
and  ||| S:1657 E:1661 ||| CC
in  ||| S:1661 E:1664 ||| IN
elderly  ||| S:1664 E:1672 ||| JJ
men  ||| S:1672 E:1676 ||| NNS
with  ||| S:1676 E:1681 ||| IN
advanced  ||| S:1681 E:1690 ||| JJ
osteoporosis ||| S:1690 E:1702 ||| NN
.  ||| S:1702 E:1704 ||| .
Particular  ||| S:1704 E:1715 ||| JJ
hopes  ||| S:1715 E:1721 ||| NNS
are  ||| S:1721 E:1725 ||| VBP
pinned  ||| S:1725 E:1732 ||| VBN
on  ||| S:1732 E:1735 ||| IN
the  ||| S:1735 E:1739 ||| DT
possibility  ||| S:1739 E:1751 ||| NN
of  ||| S:1751 E:1754 ||| IN
applying  ||| S:1754 E:1763 ||| VBG
PTH  ||| S:1763 E:1767 ||| NNP
in  ||| S:1767 E:1770 ||| IN
the  ||| S:1770 E:1774 ||| DT
therapy  ||| S:1774 E:1782 ||| NN
of  ||| S:1782 E:1785 ||| IN
post-steroid  ||| S:1785 E:1798 ||| JJ
osteoporosis ||| S:1798 E:1810 ||| NN
,  ||| S:1810 E:1812 ||| ,
mainly  ||| S:1812 E:1819 ||| RB
to  ||| S:1819 E:1822 ||| TO
suppress  ||| S:1822 E:1831 ||| VB
bone  ||| S:1831 E:1836 ||| JJ
formation ||| S:1836 E:1845 ||| NN
,  ||| S:1845 E:1847 ||| ,
the  ||| S:1847 E:1851 ||| DT
most  ||| S:1851 E:1856 ||| RBS
important  ||| S:1856 E:1866 ||| JJ
pathological  ||| S:1866 E:1879 ||| JJ
process  ||| S:1879 E:1887 ||| NN
in  ||| S:1887 E:1890 ||| IN
this  ||| S:1890 E:1895 ||| DT
regard ||| S:1895 E:1901 ||| NN
.  ||| S:1901 E:1903 ||| .
The  ||| S:1903 E:1907 ||| DT
relatively  ||| S:1907 E:1918 ||| RB
short  ||| S:1918 E:1924 ||| JJ
therapy  ||| S:1924 E:1932 ||| NN
period  ||| S:1932 E:1939 ||| NN
with  ||| S:1939 E:1944 ||| IN
a  ||| S:1944 E:1946 ||| DT
PTH  ||| S:1946 E:1950 ||| NNP
analogue  ||| S:1950 E:1959 ||| NNS
( ||| S:1959 E:1960 ||| -LRB-
24  ||| S:1960 E:1963 ||| CD
months ||| S:1963 E:1969 ||| NNS
)  ||| S:1969 E:1971 ||| -RRB-
should  ||| S:1971 E:1978 ||| MD
then  ||| S:1978 E:1983 ||| RB
be  ||| S:1983 E:1986 ||| VB
replaced  ||| S:1986 E:1995 ||| VBN
and  ||| S:1995 E:1999 ||| CC
continued  ||| S:1999 E:2009 ||| VBD
by  ||| S:2009 E:2012 ||| IN
anti-resorptive  ||| S:2012 E:2028 ||| JJ
treatment ||| S:2028 E:2037 ||| NN
.  ||| S:2037 E:2039 ||| .
